WHO WE ARE

Foreword

INA-RESPOND (Indonesia Research Partnership on Infectious Diseases) is a national clinical research network established as a bilateral partnership between the Governments of Indonesia and the United States, with a shared commitment to advancing high quality research on infectious diseases of national and global importance.

Established as a bilateral partnership between the Governments of Indonesia and the United States, represented by the Ministry of Health of the Republic of Indonesia and the U.S. National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), INA-RESPOND connects hospitals, laboratories, and research institutions across Indonesia to deliver high quality, multicenter clinical research.

The network generates robust scientific evidence to inform clinical practice, strengthen public health policy, and support timely responses to infectious disease threats. Through its coordinated, multisite platform, INA-RESPOND enables collaborative research that meets international scientific and ethical standards.

Since its establishment, INA-RESPOND has contributed to national and global scientific advancement through its research, publications, and capacity building initiatives. The network has also demonstrated its ability to respond to emerging public health challenges, including during global health emergencies such as the COVID-19 pandemic.

In its current phase, INA-RESPOND is strengthening governance and institutional integration within the Ministry of Health. Under the Directorate General of Advanced Health (Keslan), RSPI Prof. Dr. Sulianti Saroso serves as the Host Institution, while the Secretariat operates within the National Brain Center Hospital (RS PON). In alignment with Ministerial Decree No. 1458 of 2023 and the establishment of the Indonesian Clinical Research Center (INA-CRC) and Clinical Research Units, INA-RESPOND is transitioning toward a CRU based network model to enhance standardization, geographic reach, and operational responsiveness.

INA-RESPOND continues to strengthen its role as a trusted and internationally connected research network, advancing collaboration, enhancing research infrastructure, and contributing to improved health outcomes in Indonesia and beyond.

A Brief History

INA-RESPOND was initiated in 2010 and officially established in 2011 as a bilateral partnership between the Governments of Indonesia and the United States in infectious disease research.

The first INA-RESPOND multicenter study, the Acute Febrile Illness Research in Indonesia (AFIRE) study conducted from 2013 to 2016, marked a key milestone in the development of the network. The study produced scientific findings that contributed to national health policy and strengthened laboratory and research systems to support responses to infectious disease outbreaks.

Since then, INA-RESPOND has continued to evolve, expanding its research scope, strengthening its contribution to outbreak response, and generating evidence to support national and global health priorities.

Our Vision

To be a leading infectious disease clinical research group that minimizes the impact of outbreaks and improves the health of people in Indonesia, the United States, and the world.

Our Mission

To conduct high quality, collaborative clinical research studies on infectious diseases and launch rapid clinical research responses to outbreaks and epidemics.

Core Value

Our Core Values (BRIGHT)

Benefit and Responsiveness
Aligned with the research priorities of Indonesia, the United States, and the global health community.
Innovation
Advancing creative and integrated approaches in the design and implementation of research.
Goal Orientation
Focused on achieving the mission and long term impact of the partnership.
High Quality and Excellence
Committed to conducting scientifically rigorous and ethically sound infectious disease research.
Trust and Teamwork
Built on respect, transparency, accountability, communication, and collaboration.

Our Strategic Goals

Goal 1 – Science and Research

Generate new knowledge, disseminate results, and promote the utilization of research findings to improve infectious diseases clinical practice, policies, and guidelines

Goal 2 – Operations and Capability

Maintain INA-RESPOND as a collaborative partnership capable of conducting high-impact studies and launching a clinical research response

Goal 3 – Collaboration and Engagement

Leverage opportunities and collaborations to support, enhance, and promote INA-RESPOND

Institutional Framework

INA-RESPOND operates within a formal bilateral framework for infectious disease research between Indonesia and the United States, established under the Implementing Arrangement between the National Institutes of Health (NIH), U.S. Department of Health and Human Services, and the Ministry of Health of the Republic of Indonesia. This arrangement is part of the broader Agreement on Scientific and Technological Cooperation signed in Jakarta on 29 March 2010.

The establishment and implementation of INA-RESPOND in Indonesia are supported by key regulatory instruments issued by the Ministry of Health, including:

Minister of Health Decree No. 285/MENKES/SK/VIII/2013 on the INA-RESPOND Team
Minister of Health Decree No. HK.01.07/MENKES/248/2017 on the Indonesia Infectious Disease Research Team

Further institutional strengthening has been formalized through:

Director General of Advanced Health Decree No. HK.02.02/D/3167/2025 on the INA-RESPOND Secretariat